News

The World Health Organization (WHO) today released its latest reports on antibacterial agents in clinical and preclinical development, and on diagnostics that are already available or in the pipeline to detect and identify priority bacteria listed in the WHO bacterial priority pathogens list (BPPL). Too few antibacterials in the pipeline First released in 2017, WHO's Analysis of antibacterial agents in clinical and preclinical development: overview and analysis 2025 assesses whether current R&D efforts are keeping pace with the urgent need for new treatments against the most dangerous drug-resistant bacteria, as identified by WHO. The Landscape analysis of commercially available and pipeline in vitro diagnostics for bacterial priority pathogens maps existing and pipeline tools to detect and identify WHO BPPL pathogens, and to perform phenotypic antimicrobial susceptibility testing (AST) and genotypic resistance testing. Without more investment in R&D, together with dedicated efforts to ensure that new and existing products reach the people who most need them, drug-resistant infections will continue to spread." The Organization specifically calls for greater investment in tools designed for resource-limited settings, including those that eliminate the need for culture and simplifying diagnostic platforms for primary and secondary care use."